Bleeding and New Cancer Diagnosis in Patients with Atherosclerosis
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064173%3A_____%2F19%3AN0000059" target="_blank" >RIV/00064173:_____/19:N0000059 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11120/19:43918746
Result on the web
<a href="https://doi.org/10.1161/CIRCULATIONAHA.119.041949" target="_blank" >https://doi.org/10.1161/CIRCULATIONAHA.119.041949</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1161/CIRCULATIONAHA.119.041949" target="_blank" >10.1161/CIRCULATIONAHA.119.041949</a>
Alternative languages
Result language
angličtina
Original language name
Bleeding and New Cancer Diagnosis in Patients with Atherosclerosis
Original language description
Background: Patients treated with antithrombotic drugs are at risk of bleeding. Bleeding may be the first manifestation of underlying cancer. Methods: We examined new cancers diagnosed in relation to gastrointestinal or genitourinary bleeding among patients enrolled in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial, and determined the hazard of new cancer diagnosis after bleeding at these sites. Results: Of 27,395 patients enrolled (mean age 68, women 21%), 2,678 (9.8%) experienced any (major or minor) bleeding, 713 (2.6%) experienced major bleeding, and 1,084 (4.0%) were diagnosed with cancer, during a mean follow-up of 23 months. Among 2,678 who experienced bleeding, 257 (9.9%) were subsequently diagnosed with cancer. Gastrointestinal bleeding was associated with a 20-fold higher hazard of new gastrointestinal cancer diagnosis (7.4% versus 0.5%, hazard ratio [HR] 20.6, 95% confidence interval [CI]: 15.2-27.8), and 1.7-fold higher hazard of new non-gastrointestinal cancer diagnosis (3.8% versus 3.1%, HR 1.70, 95% CI: 1.20-2.40). Genitourinary bleeding was associated with a 32-fold higher hazard of new genitourinary cancer diagnosis (15.8% versus 0.8%, HR 32.5, 95% CI: 24.7-42.9) and urinary bleeding was associated with a 98-fold higher hazard of new urinary cancer diagnosis (14.2% versus 0.2%, HR 98.5, 95% CI: 68.0-142.7). Non-gastrointestinal, non-genitourinary bleeding was associated with a 3-fold higher hazard of non-gastrointestinal, non-genitourinary cancers (4.4% versus 1.9%, HR 3.02, 95% CI: 2.32-3.91). Conclusions: In patients with atherosclerosis treated with antithrombotic drugs, any gastrointestinal or genitourinary bleeding was associated with higher rates of new cancer diagnosis. Any gastrointestinal or genitourinary bleeding should prompt investigation for cancers at these sites. Clinical Trial Registration: URL: https://www.clinicaltrials.gov. Unique Identifier: NCT01776424.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30201 - Cardiac and Cardiovascular systems
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2019
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Circulation
ISSN
0009-7322
e-ISSN
1524-4539
Volume of the periodical
140
Issue of the periodical within the volume
18
Country of publishing house
US - UNITED STATES
Number of pages
9
Pages from-to
1451-1459
UT code for WoS article
000493073500008
EID of the result in the Scopus database
2-s2.0-85073968029